190
Views
46
CrossRef citations to date
0
Altmetric
Original Article

Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men

, &
Pages 1415-1422 | Accepted 16 Mar 2007, Published online: 11 May 2007
 

ABSTRACT

Objective: Posaconazole is an extended-spectrum triazole antifungal agent for the treatment and prophylaxis of invasive fungal infections. This randomized, open-label, parallel-group, multiple-dose study was conducted in healthy adult volunteers to assess the potential for a drug interaction between phenytoin and the posaconazole tablet formulation.

Methods: Subjects were randomly assigned for 10 days to one of the following treatments: posaconazole (200 mg once daily), phenytoin (200 mg once daily), or posacon­azole (200 mg once daily) and phenytoin (200 mg once daily). Blood samples were collected on days 1 and 10 for pharmacokinetic evaluation of posaconazole and pheny­toin concentrations.

Results: A total of 36 healthy men enrolled in the study. On day 1, the maximum plasma concentration (Cmax) and area under the concentration–time curve calculated from time 0–24 h post-dose (AUC(0–24)) were unchanged upon co-administration. At steady state (day 10), co-administra­tion of posaconazole with phenytoin resulted in 44% ( p = 0.012) and 52% ( p = 0.007) decreases in posaconazole Cmax and AUC(0–24), respectively. These decreases in exposure corresponded with a 90% increase in steady-state clearance of orally administered posaconazole. Phenytoin Cmax and AUC(0–24) were not significantly altered upon co-administration of the two agents, 24% increase in Cmax ( p = 0.196) and 25% increase in AUC(0–24) ( p = 0.212) values, although inter-subject variability was observed within this group.

Conclusion: Because co-administration of phenytoin and posaconazole significantly reduces posaconazole exposure and increases phenytoin levels in some subjects, concomitant use of these agents should be avoided unless the benefit outweighs the risk.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.